MaxCyte (MXCT) investor relations material

Akron Bio acquisition

• $150 million acquisition adds a 20-year cytokine and growth-factor reagent supplier, extending offerings across viral and non-viral ex vivo cell therapy.

• Akron has grown at a 13% CAGR since 2018, contributes $28 million in revenue and $7 million-$8 million in EBITDA, and is expected to support revenue above $60 million next year.

• Reagent differentiation includes stable, high-quality liquid products usable in closed manufacturing systems, a drug master file, and specification in four commercial therapies plus four registrational programs.

• Akron’s commercial team will remain in place; U.S. teams are complementary, while existing Europe and Asia Pacific teams can expand Akron’s reach outside the U.S. through gradual integration.

• Akron growth is expected at early-to-mid teens next year; commercial-program scaling and sales synergies may lift growth over time, but benefits will take time to emerge.

Integration and financial outlook

• Estimated $3 million-$4 million in cost savings, primarily from overlapping corporate and G&A functions, with savings expected to begin in H2 next year.

• Akron’s addition is expected to bring gross margin to the early 70% range; operational improvements and rising commercial revenue could improve margins further over time.

• Forecast cash burn moves from $17 million for this year to below $10 million next year, including Akron and existing business growth.

• Integration risk is viewed as lower given Akron’s established leadership, 20-year operating history, four commercial programs, and complementary commercial teams.

Market conditions and core business

• Cell-therapy funding was $3 billion in 2024 and $3.5 billion in 2025; 2026 funding is expected to be similar to 2025, with investment concentrated in later-stage programs.

• More than 90% of therapy assets are ex vivo and fewer than 10% are in vivo; most in vivo programs remain preclinical, while commercial and late-stage programs are ex vivo.

• Program rationalization in 2025 is largely behind; 13 active programs across 12 developers are mostly lead assets, with additional preclinical programs expected to enter clinical development.

• Q3 instrument growth remained double-digit excluding Genentech; the funnel spans research through GMP manufacturing and across the instrument portfolio.

• Inventory drawdowns at the largest customer are behind, with growth now visible; recurring PA revenue is expected to show mid-single-digit growth next year.